Fujimoto S, Akao T, Itoh B, Koshizuka I, Koyano K
Ann Surg. 1977 Apr;185(4):462-6. doi: 10.1097/00000658-197704000-00016.
Studies of oral chemotherapy of 5-fluroruracil (5-FU) combined with FT-207, a furanyl analog of 5-FU, as an adjuvant to surgical treatment of stomach cancer have been performed since 1970 in the first department of surgery of Chiba University, Japan. These studies were performed on 107 patients with curative stomach cancer and 22 patients with non-curative stomach cancer. These patients received consecutively 3.5mg/kg/day of 5-FU and 8mg/kg/day of FT-207 for 24 to 36 months and were compared with control patients who had undergone only surgical treatment. A significant higher survival was observed in the curatively resected patients receiving oral 5-FU and FT-207, as compared to the control group. Studies on non-curative stomach cancer patients treated with the same dose schedule gave encouraging results. Because of the limited number of patients treated in this study, the drawing of reliable conclusions must wait the results of further studies.
自1970年起，日本千叶大学第一外科开展了关于5-氟尿嘧啶（5-FU）联合FT-207（5-FU的呋喃类似物）进行口服化疗作为胃癌手术治疗辅助手段的研究。这些研究针对107例根治性胃癌患者和22例非根治性胃癌患者进行。这些患者连续24至36个月每日接受3.5mg/kg的5-FU和8mg/kg的FT-207治疗，并与仅接受手术治疗的对照组患者进行比较。与对照组相比，接受口服5-FU和FT-207治疗的根治性切除患者的生存率显著更高。对采用相同剂量方案治疗的非根治性胃癌患者的研究也取得了令人鼓舞的结果。由于本研究中接受治疗的患者数量有限，得出可靠结论还需等待进一步研究的结果。
